Nai-Jung Chiang

Nai-Jung Chiang, Attending Physician & Associate Professor

Attending Physician, Department of Oncology, Taipei Veterans General Hospital
Organization: Department of Oncology, Taipei Veterans General Hospital
Nationality: Taiwan
Email: njchiang@vghtpe.gov.tw

Brief Introduction

Dr. Nai-Jung Chiang is a medical oncologist at Taipei Veterans General Hospital, Associate Professor at National Yang Ming Chiao Tung University, and Adjunct Assistant Investigator at the National Institute of Cancer Research, National Health Research Institutes, Taiwan. She specializes in gastrointestinal malignancies, particularly pancreatic and biliary tract cancers.

Her research focuses on investigator-initiated clinical trials, translational oncology, and precision cancer medicine. She has led multiple prospective clinical studies and nationwide collaborative programs investigating biomarker-guided therapies, immunotherapy, and molecular profiling in gastrointestinal cancers. Her work has contributed to the development of precision oncology strategies in biliary tract cancer and has been published in leading journals, including The Lancet, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, and NPJ Precision Oncology. Dr. Chiang currently serves on the Scientific Committee for Gastrointestinal Tumors of the 2025 ESMO Asia Congress and is actively involved in international collaborative research in gastrointestinal oncology.

Specialty

  • Gastrointestinal cancer
  • Precision Oncology
  • Design and execution of investigator-initiated clinical trials

Education

  • 1998.8 – 2005.7: M.D., College of Medicine, National Defense Medical University, Taipei, Taiwan
  • 2014 – 2020: Ph.D., Institute of Clinical Medicine, College of Medicine, National Cheng Kung University

Experience

  • 2022 - Present: Attending Physician, Department of Oncology, Taipei Veterans General Hospital
  • 2022 - Present: Adjunct Assistant Investigator & Attending physician, National Institute of Cancer Research, NHRI
  • 2020.4 - 2022.02: Assistant Investigator & Attending physician, National Institute of Cancer Research, NHRI
  • 2020.4 - 2022.02: Attending physician, Department of Oncology, National Cheng Kung University hospital

Selected Publications

  1. Hsieh CC, Chiang NJ, Wang SJ, Chen LT, Yang CS, Shen CH. Nanotechnology-based reformulation of AUY922 mitigates retinal toxicity and retains potent anti-tumor activity. Nanomedicine. 2026:74:102957. (*Co-first author)
  2. Chiang NJ, Su YY, Ho IW, Bai LY, Li CP, Chen JS, Hsiao CF, Tsou HH, Hsu C, Chiu TJ, Hsieh YY, Rau KM, Ho CL, Shan YS, Chen LT. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). Eur J Cancer. 2026;235:116229.
  3. Chiang NJ, Tang CY, Bai LY, Chang PC, Chen WM, Kang ST, Chen SC, Chen MH, Hsieh CH. Circulating miRNAs as potentially predictive biomarkers for chemoimmunotherapy in advanced biliary tract cancer: a post-hoc analysis of the phase II T1219 study. NPJ Precis Oncol. 2025;9(1):307.
  4. Chiang NJ, Lee JH, Chen MH, Chao Y, Su WC, Bai LY, Wu SY, Hsu CH, Shan YS, Li CP, Chen SH, Chung WP, Hao WH, Chen LT, Lin CC. Phase I study of oral metronomic gemcitabine (D07001) in patients with advanced solid tumors. Oncologist. 2025;30(4):oyaf051.
  5. Chiang NJ, Bai LY, Ho IW, Hsu CH, Liang YS, Chiu CF, Lin CC, Chang KY, Chen SH, Tsai HJ, Lin YP, Chen LT, Lin CC. A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors. Invest New Drugs. 2025;43(3):709-718.
  6. Chen IS, Hsieh CC, Li CC, Wei YL, Cheng CC, Feng SW, Lee HL, Chiang NJ*, Shen CH*, Hsu HP*. ACSL6 modulates docosahexaenoic acid-induced cytotoxicity to potentiate chemotherapy response in colorectal and breast cancer. Oncogenesis. 2025;14(1):45. (*Co-corresponding author)
  7. Tang CY, Lin YT, Yeh YC, Chung SY, Chang YC, Hung YP, Chen SC, Chen MH, Chiang NJ. The correlation between LAG-3 expression and the efficacy of chemoimmunotherapy in advanced biliary tract cancer. Cancer Immunol Immunother. 2025;74(2):41.
  8. Chung SY, Yeh YC, Huang CJ, Chiang NJ, Dennis Hsu, Chan MH, Lu ML, Hsu TS, Hung YP, Yeh CN, Michael Hsiao, Chang YC, Wang YC, Chen MH. Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma. J Immunother Cancer. 2025;13(1):e010173.
  9. Hsieh CC, Li TW, Li CC, Chen SH, Wei YL, Chiang NJ*, Shen CH*. DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer. Oncogenesis. 2024;13(1):34. (*Co-corresponding author)
  10. Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, Chen MH. Impaired Chromatin Remodeling Predicts Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. Clin Cancer Res. 2022;28(19):4248-4257.
The application of NALIRIFOX in the treatment of pancreatic cancer and further perspectives (ONIVYDE®)
Nai-Jung Chiang MD, PhD
Department of Oncology, Taipei Veterans General Hospital, Taiwan
School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging malignancies, and its treatment has evolved toward multimodality management, individualized therapeutic sequencing, and precision oncology. Liposomal irinotecan (nal-IRI, ONIVYDE®) has become an important component of this paradigm. Following its establishment as the standard second-line therapy in the NAPOLI-1 trial, the NAPOLI-3 study further positioned NALIRIFOX as a first-line option for metastatic PDAC by demonstrating superior progression-free and overall survival compared with gemcitabine plus nab-paclitaxel. Emerging data also indicate favorable efficacy and tolerability in Asian patients.

This lecture will review the evolving role of ONIVYDE® across the PDAC treatment continuum, integrating evidence from pivotal clinical trials with extensive real-world experience from Taiwan. Practical aspects of treatment optimization—including dose intensity, treatment sequencing, prior irinotecan exposure, and patient selection—will be highlighted, together with emerging data on S-1-based combinations.

Beyond metastatic disease, NALIRIFOX is increasingly being investigated in perioperative treatment for resectable and borderline resectable PDAC to improve surgical outcomes and expand opportunities for curative resection. Ongoing studies combining NALIRIFOX with radiotherapy, targeted therapies, antibody-drug conjugates, and immunotherapy may further broaden its clinical applications. Integration of molecular profiling, circulating biomarkers, and precision oncology is expected to refine patient selection and optimize treatment strategies.

Collectively, these advances position ONIVYDE® as an integral component of multidisciplinary PDAC management. Future progress will depend on biomarker-guided treatment selection, rational combination strategies, and personalized therapeutic approaches to further improve patient outcomes.